Clinical Trials Browser

Phase 2 × Peritoneal Diseases × Gemcitabine × Clear all

NCT02850874 2022-04-27

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms, Peritoneal Diseases